Abstract
The trypsin-like serine protease factor Xa (fXa) is located at the convergence point of the intrinsic and extrinsic coagulation cascade, and therefore has emerged as an attractive target for the design of novel anticoagulants. During the development of substrate-analogue urokinase inhibitors we have found that the protection of the P3-DSer side chain leads to a scaffold of potent fXa inhibitors with the general structure R1-SO2-DSer(R2)-Gly-4-amidinobenzylamide. The first lead (3) with an N-terminal benzylsulfonyl group and DSer(tBu) as P3 residue inhibits human fXa with a Ki of 14 nM. A variety of derivatives with modified P4, P3, and P2 residues have been investigated in terms of inhibition of fXa and related proteases and for their anticoagulant potency and elimination behaviour. Most inhibitors were rapidly cleared from the circulation of rats. However, compound 48 (Ki = 3.5 nM), one of the most potent and selective inhibitors containing a DArg as P3 residue was relatively slowly eliminated (t_ ≉ 1h). Inhibitor 48 doubled clotting times in human plasma at 0.32 μM (aPTT) and 0.28 μM (PT), and is approximately 10-fold more potent than the reference fXa inhibitor DX-9065a in the inhibition of the prothrombinase complex. The structures of two inhibitors in complex with human fXa were solved by X-ray crystallography.
Keywords: antithrombotics, anticoagulants, protease inhibitor, Factor Xa
Medicinal Chemistry
Title: New Substrate Analogue Inhibitors of Factor Xa Containing 4-Amidinobenzylamide as P1 Residue: Part 1
Volume: 2 Issue: 4
Author(s): Torsten Steinmetzer, Jorg Sturzebecher, Oliver Schuster, Uta Sturzebecher, Andrea Schweinitz and Anne Sturzebecher
Affiliation:
Keywords: antithrombotics, anticoagulants, protease inhibitor, Factor Xa
Abstract: The trypsin-like serine protease factor Xa (fXa) is located at the convergence point of the intrinsic and extrinsic coagulation cascade, and therefore has emerged as an attractive target for the design of novel anticoagulants. During the development of substrate-analogue urokinase inhibitors we have found that the protection of the P3-DSer side chain leads to a scaffold of potent fXa inhibitors with the general structure R1-SO2-DSer(R2)-Gly-4-amidinobenzylamide. The first lead (3) with an N-terminal benzylsulfonyl group and DSer(tBu) as P3 residue inhibits human fXa with a Ki of 14 nM. A variety of derivatives with modified P4, P3, and P2 residues have been investigated in terms of inhibition of fXa and related proteases and for their anticoagulant potency and elimination behaviour. Most inhibitors were rapidly cleared from the circulation of rats. However, compound 48 (Ki = 3.5 nM), one of the most potent and selective inhibitors containing a DArg as P3 residue was relatively slowly eliminated (t_ ≉ 1h). Inhibitor 48 doubled clotting times in human plasma at 0.32 μM (aPTT) and 0.28 μM (PT), and is approximately 10-fold more potent than the reference fXa inhibitor DX-9065a in the inhibition of the prothrombinase complex. The structures of two inhibitors in complex with human fXa were solved by X-ray crystallography.
Export Options
About this article
Cite this article as:
Steinmetzer Torsten, Sturzebecher Jorg, Schuster Oliver, Sturzebecher Uta, Schweinitz Andrea and Sturzebecher Anne, New Substrate Analogue Inhibitors of Factor Xa Containing 4-Amidinobenzylamide as P1 Residue: Part 1, Medicinal Chemistry 2006; 2 (4) . https://dx.doi.org/10.2174/157340606777724040
DOI https://dx.doi.org/10.2174/157340606777724040 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Obstetrical Hemorrhage Review
Current Women`s Health Reviews Ultrasound Augmented Thrombolysis
Current Medical Imaging Veno-Arterial Extracorporeal Membrane Oxygenation in the Adult: A Bridge to the State of the Art
Current Cardiology Reviews A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
Current Pharmaceutical Design Warfarin Pharmacogenomics: Recommendations With Available Patented Clinical Technologies
Recent Patents on Biotechnology Basic Mechanisms in Atherosclerosis: The Role of Calcium
Medicinal Chemistry Protrhombotic Effects of Contraceptives
Current Pharmaceutical Design An Overview of Neolignans of the Genus Piper L.: Isolation Methods and Biological Activities
Mini-Reviews in Medicinal Chemistry Nitric Oxide and Dietary Factors: Part V Summary/Conclusion and References
Vascular Disease Prevention (Discontinued) Behcets Syndrome: Literature Review
Current Rheumatology Reviews Iatrogenic Right Atrial Thrombus Complicated by Pulmonary Embolism: Management and Outcomes
Current Cardiology Reviews The Start of a New Era for Stroke Treatment: Mechanical Thrombectomy Devices
Current Neurovascular Research Ultra-performance LC-ESI/Q-TOF MS for the Rapid Analysis of Rivaroxaban: Method Validation Using Experimental Design for Robustness Evaluation
Current Analytical Chemistry Thromboembolism with Immunomodulatory Agents in the Treatment of Multiple Myeloma
Cardiovascular & Hematological Agents in Medicinal Chemistry Platelets in Thrombosis and Hemostasis: Old Topic with New Mechanisms
Cardiovascular & Hematological Disorders-Drug Targets Novel uses of Imaging in AF Ablation
Recent Patents on Cardiovascular Drug Discovery Clinical Applications of Transcranial Doppler Sonography
Reviews on Recent Clinical Trials Interventional Radiology in Paediatrics
Current Pediatric Reviews Small Peptides as Modulators of Serine Proteases
Current Medicinal Chemistry Restoring the Dysfunctional Endothelium
Current Pharmaceutical Design